A CARDIOMYOPATHY REGISTRY
The goal of the Sarcomeric Human Cardiomyopathy Registry (SHaRe), a first-of- its-kind effort, is to advance the understanding of hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM), two types of heritable heart disease affecting nearly 2.4 million adults and children in the U.S. and Europe.
SHaRe is a multi-center, international repository of clinical and laboratory data on individuals and families with genetic heart disease developed as a collaboration with several world-leading cardiovascular centers.
By building the world’s most robust database of its kind, cardiovascular geneticists and research-based cardiologists will be able to expand their knowledge base and generate fresh insights and research initiatives supporting the development of more targeted and effective approaches in the treatment of genetic heart disease.
Funded by research grants from MyoKardia, Inc., SHaRe brings together an expert group of experienced and knowledgeable cardiologists and geneticists from the United States, Europe and South America with a passion for helping people with genetic heart disease.
Through our website and Affairs of the Heart patient conferences, SHaRe seeks to educate patients and family members about the scientific findings from the registry and about advances in the diagnosis, treatment and management of HCM and DCM.
To download our brochure, click here.
Stay Connected: Join our mailing list for updates on research, treatments, clinical trials and events.
Join our mailing list for updates on research, treatments, clinical trials and events.
International SHaRe Locations Around the World